Guardant Health, Inc. (GH): Price and Financial Metrics
Guardant Health, Inc. (GH)
Today's Latest Price: $106.66 USD
Updated Oct 30 4:00pm
Add GH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
GH Stock Summary
- GH's went public 2.08 years ago, making it older than only 4.17% of listed US stocks we're tracking.
- GH's price/sales ratio is 41.17; that's higher than the P/S ratio of 95.22% of US stocks.
- With a year-over-year growth in debt of 26,599.35%, Guardant Health Inc's debt growth rate surpasses 99.77% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Guardant Health Inc, a group of peers worth examining would be LASR, ACAD, ETON, ESTC, and BMRN.
- GH's SEC filings can be seen here. And to visit Guardant Health Inc's official web site, go to guardanthealth.com.
GH Stock Price Chart Interactive Chart >
GH Price/Volume Stats
| Current price | $106.66 | 52-week high | $114.33 |
| Prev. close | $109.68 | 52-week low | $55.90 |
| Day low | $105.30 | Volume | 569,000 |
| Day high | $109.60 | Avg. volume | 1,042,645 |
| 50-day MA | $102.73 | Dividend yield | N/A |
| 200-day MA | $85.77 | Market Cap | 10.60B |
Guardant Health, Inc. (GH) Company Bio
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.
Loading social stream, please wait...